AAAAAA

   
Results: 1-15 |
Results: 15
Gemcitabine plus etoposide in chemonaive extensive disease small-cell lungcancer: A multi-centre phase II study
Authors: Vansteenkiste, J Gatzemeier, U Manegold, C Hanauske, A Weynants, P Bosquee, L Blatter, J Mansouri, K von Pawel, J
Citation: J. Vansteenkiste et al., Gemcitabine plus etoposide in chemonaive extensive disease small-cell lungcancer: A multi-centre phase II study, ANN ONCOL, 12(6), 2001, pp. 835-840
Phase II comparator study of oral versus intravenous topotecan in patientswith chemosensitive small-cell lung cancer
Authors: von Pawel, J Gatzemeier, U Pujol, JL Moreau, L Bildat, S Ranson, M Richardson, G Steppert, C Riviere, A Camlett, I Lane, S Ross, G
Citation: J. Von Pawel et al., Phase II comparator study of oral versus intravenous topotecan in patientswith chemosensitive small-cell lung cancer, J CL ONCOL, 19(6), 2001, pp. 1743-1749
Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: Results of a multicenter phase II study
Authors: Schuler, M Herrmann, R De Greve, JLP Stewart, AK Gatzemeier, U Stewart, DJ Laufman, L Gralla, R Kuball, J Buhl, R Heussel, CP Kommoss, F Perruchoud, AP Shepherd, FA Fritz, MA Horowitz, JA Huber, C Rochlitz, C
Citation: M. Schuler et al., Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: Results of a multicenter phase II study, J CL ONCOL, 19(6), 2001, pp. 1750-1758
Indications for chemotherapy in stage IV non-small cell lung cancer
Authors: Gatzemeier, U
Citation: U. Gatzemeier, Indications for chemotherapy in stage IV non-small cell lung cancer, LUNG CANC, 33, 2001, pp. S109-S113
Phase II study of docetaxel alternating with cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer
Authors: Mattson, K Vansteenkiste, J Stupp, R Bargetzi, M Saarinen, A Jekunen, A Fillet, G Teixeira, M Gatzemeier, U Olivares, R Soussan-Lazard, K Berille, J
Citation: K. Mattson et al., Phase II study of docetaxel alternating with cisplatin in chemotherapy-naive patients with advanced non-small cell lung cancer, ANTI-CANC D, 11(1), 2000, pp. 7-13
Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA (TM)) and cisplatin: A multicenter phase II trial
Authors: Manegold, C Gatzemeier, U von Pawel, J Pirker, R Malayeri, R Blatter, J Krejcy, K
Citation: C. Manegold et al., Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA (TM)) and cisplatin: A multicenter phase II trial, ANN ONCOL, 11(4), 2000, pp. 435-440
Does salvage therapy influence outcome? In reply
Authors: Gatzemeier, U Gallant, G Bogaerts, J
Citation: U. Gatzemeier et al., Does salvage therapy influence outcome? In reply, J CL ONCOL, 19(7), 2000, pp. 2108-2109
Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group
Authors: von Pawel, J von Roemeling, R Gatzemeier, U Boyer, M Elisson, LO Clark, P Talbot, D Rey, A Butler, TW Hirsh, V Olver, I Bergman, B Ayoub, J Richrdson, G Dunlop, D Arcenas, A Vescio, R Viallet, J Treat, J
Citation: J. Von Pawel et al., Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group, J CL ONCOL, 18(6), 2000, pp. 1351-1359
Phase III comparative study of high-dose cisplatin versus a combination ofpaclitaxel and cisplatin in patients with advanced non-small-cell lung cancer
Authors: Gatzemeier, U von Pawel, J Gottfried, M ten Velde, GPM Mattson, K DeMarinis, F Harper, P Salvati, F Robinet, G Lucenti, A Bogaerts, J Gallant, G
Citation: U. Gatzemeier et al., Phase III comparative study of high-dose cisplatin versus a combination ofpaclitaxel and cisplatin in patients with advanced non-small-cell lung cancer, J CL ONCOL, 18(19), 2000, pp. 3390-3399
Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer
Authors: Sandler, AB Nemunaitis, J Denham, C von Pawel, J Cormier, Y Gatzemeier, U Mattson, K Manegold, C Palmer, MC Gregor, A Nguyen, B Niyikiza, C Einhorn, LH
Citation: Ab. Sandler et al., Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer, J CL ONCOL, 18(1), 2000, pp. 122-130
Options for treatment of lung cancer with irinotecan
Authors: Gatzemeier, U
Citation: U. Gatzemeier, Options for treatment of lung cancer with irinotecan, ONKOLOGIE, 23, 2000, pp. S34-S36
Topotecan in second-line therapy of SCLC: Impact on survival?
Authors: Huber, RM Gatzemeier, U Gosse, H von Pawel, J Hruska, D Mezger, J Saal, JG Kleinschmidt, R Steppert, C Steppling, H
Citation: Rm. Huber et al., Topotecan in second-line therapy of SCLC: Impact on survival?, ONKOLOGIE, 23, 2000, pp. 9-12
Lenograstim as support for ACE chemotherapy of small-cell lung cancer - A phase III, multicenter, randomized study
Authors: Gatzemeier, U Kleisbauer, JP Drings, P Kaukel, E Samaras, N Melo, MJ Cardenal, F Robinet, G Snijder, RJ von Pawel, J Palisses, R
Citation: U. Gatzemeier et al., Lenograstim as support for ACE chemotherapy of small-cell lung cancer - A phase III, multicenter, randomized study, AM J CL ONC, 23(4), 2000, pp. 393-400
Single-agent paclitaxel in advanced non-small-cell lung cancer
Authors: Gatzemeier, U
Citation: U. Gatzemeier, Single-agent paclitaxel in advanced non-small-cell lung cancer, ONCOLOGY-NY, 13(9), 1999, pp. 22-25
Hycamtin in the therapy of non-small-cell lung cancer
Authors: Gatzemeier, U
Citation: U. Gatzemeier, Hycamtin in the therapy of non-small-cell lung cancer, ONKOLOGIE, 21, 1998, pp. 18-21
Risultati: 1-15 |